Drug Trial Radar · NCT01449370
Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
Last checked: Nov 19, 2026Latest source record: Mar 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
125
Actual
Start
Oct 2011
Primary completion
Jul 2015
Study completion Jan 2016
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- First posted
- Oct 10, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or optimal biologic dose(OBD), safety and tolerability, dose-limiting toxicity (DLT) of TAK-117 when administered orally in subjects with advanced solid malignancies.
Conditions
- Metastatic Solid Tumors
Interventions
TAK-117Drug
oral administration of TAK-117, daily and intermittent schedules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) of TAK-117Time frame: Baseline up to Cycle 1 Day 21
- Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Death, Adverse Events (AEs) Leading to Discontinuation of Study Drug, and DLTs in Cycle 1Time frame: Baseline up to Cycle 27 Day 45
- Number of Participants With Highest Level of TEAEs SeverityTime frame: Baseline up to Cycle 27 Day 45
- Number of Participants With Clinically Meaningful Changes in Laboratory ValuesTime frame: Baseline up to Cycle 27 Day 45
- Number of Participants With Clinically Meaningful Changes in Vital SignsTime frame: Baseline up to Cycle 27 day 45
- Number of Participants With Clinically Meaningful Changes in Electrocardiogram (ECG)Time frame: Baseline up to Cycle 27 Day 45
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Site not named
Boston, Massachusetts
Site not named
Detroit, Michigan
Site not named
Dallas, Texas
Site not named
Barcelona, Spain
Site not named
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.